Department of Internal Medicine, University of Southern California, Los Angeles, CA, USA.
Division of Gastrointestinal and Liver Diseases, Department of Medicine, University of Southern California, Los Angeles, CA, USA.
J Gen Intern Med. 2022 Oct;37(13):3435-3443. doi: 10.1007/s11606-022-07628-9. Epub 2022 Apr 28.
Elimination of hepatitis C virus (HCV), a leading cause of liver disease in the USA and globally, has been made possible with the advent of highly efficacious direct acting antivirals (DAAs). DAA regimens offer cure of HCV with 8-12 weeks of a well-tolerated once daily therapy. With increasingly straightforward diagnostic and treatment algorithms, HCV infection can be managed not only by specialists, but also by primary care providers. Engaging primary care providers greatly increases capacity to diagnose and treat chronic HCV and ultimately make HCV elimination a reality. However, barriers remain at each step in the HCV cascade of care from screening to evaluation and treatment. Since primary care is at the forefront of patient contact, it represents the ideal place to concentrate efforts to identify barriers and implement solutions to achieve universal HCV screening and increase curative treatment.
消除丙型肝炎病毒(HCV),这是美国和全球肝病的主要原因,随着高效直接作用抗病毒药物(DAA)的出现成为可能。DAA 方案通过每天一次的耐受性良好的 8-12 周治疗提供 HCV 的治愈。随着越来越简单的诊断和治疗算法,不仅可以由专家,还可以由初级保健提供者来管理 HCV 感染。通过初级保健提供者,大大增加了诊断和治疗慢性 HCV 的能力,并最终使 HCV 消除成为现实。然而,在 HCV 护理链的每个环节,从筛查到评估和治疗,仍然存在障碍。由于初级保健处于与患者接触的最前沿,因此它是集中精力识别障碍并实施解决方案以实现普遍 HCV 筛查和增加治疗效果的理想场所。